SESN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 18, 2021 in the Class Action Filed on Behalf of Sesen Bio, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - October 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sesen Bio, Inc. (NASDAQ: SESN) alleging that the Company violated federal securities laws.

Class Period: December 21, 2020 and August 17, 2021
Lead Plaintiff Deadline: October 18, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SESN:
https://www.kleinstocklaw.com/pslra-1/sesen-bio-inc-loss-submission-form?id=20377&from=5

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/99487_451222_logo.jpg

Sesen Bio, Inc. NEWS - SESN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Sesen Bio you have until October 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Sesen Bio securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SESN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99487

info